sur Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations' Inka Health Partners with AstraZeneca Canada
Onco-Innovations Limited announced that its subsidiary, Inka Health Corp., has signed a new analytical contract with AstraZeneca Canada. This agreement, finalized on March 20, 2025, aims to support real-world evidence (RWE) research within Canada's regulatory environment.
The project will focus on creating a peer-reviewed manuscript examining the role of international RWE in submissions to Canada's Drug Agency. This study highlights the strategic use of data generated outside Canada, a significant interest within oncology and pharmaceuticals.
This collaboration builds on prior work under the AZ Services Agreement. Inka Health previously conducted a comprehensive review addressing bias in RWE. Findings were accepted for presentation at ISPOR 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Onco-Innovations Limited